Effect of the pneumococcal conjugate vaccine on pneumococcal carriage in Turkish children

Abstract

The aim of our study was to evaluate the effect of the seven-valent pneumococcal conjugate vaccine which has recently been included in the national immunization schedule on the nasopharyngeal carriage of Streptococcus pneumoniae in a group of healthy Turkish children. This is the first study determining the efficacy of this vaccine in Turkey. One hundred and thirty-eight children who had completed their pneumococcal vaccination series and 109 unvaccinated control subjects aged 12-59 months were included in the study between October 2007 and April 2008. A single nasopharyngeal swab sample was obtained from each subject. S. pneumoniae was isolated in 32 (12.9%) of 247 subjects. No significant differences were detected in pneumococcal carriage rate between the vaccinees and controls (10.1% vs 16.5%). Prevalence of vaccine type (VT) carriage was statistically lower in the vaccinated group than the controls while non-vaccine type carriage (NVT) was similar. Most frequently isolated vaccine serotype was 23F in the vaccinated group and 19F in the non-vaccinated group. Of the isolated S. pneumoniae, 13.3% were penicillin susceptible and 86.7% were non-susceptible. Vaccinees and controls did not differ statistically with respect to carriage rate of penicillin-resistant S. pneumoniae. All the pneumococcal isolates were susceptible to ceftriaxone, vancomycin, rifampicin and quinolones. Seven-valent conjugate vaccine induces long-term protection against carriage of VT S. pneumoniae in Turkish children. The ability of the conjugate vaccine to reduce transmission of antibiotic resistant S. pneumoniae may be possible if its introduction is coupled with a reduction in inappropriate use of antibiotics.